Navigation Links
Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Date:10/20/2011

LA JOLLA, Calif., Oct. 20, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and collaborators at NYU Langone Medical Center and Wake Forest Baptist Medical Center today announced the publication of new pre-clinical research findings in the journal Nature (Rayner et al., Nature, October 20, 2011). The new data show the first demonstration of marked increases in high density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and suppression of plasma triglyceride levels in non-human primates through inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with proprietary chemically modified anti-miR oligonucleotides. A webinar to discuss the new data will be hosted by Regulus and features Kathryn Moore, Ph.D., associate professor in the Department of Medicine at NYU Langone Medical Center and Regulus scientists (11:00am EDT, October 26, 2011).

"In addition to atherosclerotic plaque regression and enhanced reverse cholesterol transport that we previously observed in rodents with our collaborators at NYU Langone Medical Center, anti-miR-33 treatment is now shown to increase HDL cholesterol and lower triglycerides in non-human primates," said Hubert C. Chen, M.D., Vice President of Translational Medicine at Regulus. "These combined data sets provide strong evidence that an anti-miR-33 therapeutic approach can offer multiple mechanisms to benefit patients with atherosclerosis. Anti-miR-33a/b is one of several microRNA therapeutic programs we are advancing toward clinical development."

Dr. Moore said, "The current study is the first to demonstrate in non-human primates that inhibition of miR-33a/b can both increase circulating levels of HDL-C and suppress plasma triglyceride levels. This study highligh
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
3. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
4. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
5. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
6. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
7. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
8. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
9. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
10. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
11. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The In Silico Drug Discovery ... be featured at the conference, which takes place at ... 3 and 4, 2014. Researchers, students, drug developers, business ... the following: KEYNOTE SPEAKERS ... Skaggs School of Pharmacy Drug Discovery with ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A ... occurring microorganisms such as bacteria, fungi, and algae ... water, methane, biomass, inorganic compounds, carbon dioxide, and ... expanding customer base and improved costs, biodegradable polymers ... economically viable alternative to conventional polymers. Primary factors ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of ... This addition to the company’s industry-leading line of ... and available in 125 or 250 gallon capacities. ... weeks or less. , The new pre-engineered TerraPure tank ... existing TerraPure tank line – plus quick turnaround. ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... 2011 Reportlinker.com announces that a new market ... Pipeline Insight: Cancer Overview- Breast and ... positive patients http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html ... three tumor types covered in this report are ...
... in French . Scientists have identified a ... by Vincent van Gogh and other artists of the late ... how to stop the bright yellow colours of van Gogh,s ... and fading over time. In the meantime, the results suggest ...
... Illinois researchers have documented the first observations of some unusual ... graphene. Led by University of Illinois physics professor Nadya ... Nature Physics . When a current is applied to ... through the material as a stream of single electrons. ...
Cached Biology Technology:Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients 2X-rays show why van Gogh paintings lose their shine 2X-rays show why van Gogh paintings lose their shine 3X-rays show why van Gogh paintings lose their shine 4Physicists isolate bound states in graphene-superconductor junctions 2
(Date:9/17/2014)... Campaigns against disposable plastic shopping bags and their environmental ... lawmakers passed the first statewide ban on the bags, ... But the plastic bag industry is not yielding without ... & Engineering News , the weekly newsmagazine of the ... with C&EN, reports that the anti-bag campaign logged its ...
(Date:9/17/2014)... of Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by ... in normal accompanying cells in colorectal tumors. Analysis ... colorectal tumors, predict the evolution of the patient ... relapses. , Biomarkers , Colorectal ... considering both sexes. About 30,000 new cases are ...
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] After decades of decline, ... Cod,s saltmarshes. To the eye, the marsh in those ... clear that a key service of the marsh ... aesthetics back but the ecosystem function hasn,t come back," ... and senior author of the study in the journal ...
Breaking Biology News(10 mins):Five genes to predict colorectal cancer relapses 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... push to document the biodiversity of the world within 25 ... known, especially when it comes to vast and often inaccessible ... world's oceans have focused on adult organisms, but new research ... its larval phase with DNA barcoding is a valuable way ...
... struggled to understand how IVIG worked. It's ability ... , Intravenous immunoglobulin (IVIG) is a complex mixture ... the pooled antibodies from thousands of people, and is ... practitioners have used it off-label with varied success in ...
... in the June issue of American Naturalist, Erika J. ... and Michael J. Donoghue (Yale University) explore how leafy, ... "The cactus form is often heralded as a striking ... in plants," write the authors. "A succulent, long-lived photosynthetic ...
Cached Biology News:New research finds surveys of larval-stage organisms effective for measuring marine biodiversity 2A single sugar found responsible for an antibody's ability to treat inflammation 2A single sugar found responsible for an antibody's ability to treat inflammation 3
... HEXALIGHT robot is based on PI's experience ... more than a decade. PI Hexapods were ... and antenna adjustments over wide ranges in ... degrees of freedom with 3 m minimum ...
... length insert sequencing service for large insert ... Agencourt utilizes unique library construction techniques ... are several features that allow Agencourt to ... turnaround including our patented magnetic bead-based SPRI ...
... The Guava EasyCyte system is the first ... with built-in 96-well microplate sampling (with tube ... cells and compounds quickly and easily, without ... having the carryover issues found with other ...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
Biology Products: